Recordati Reports Strong Growth and Strategic Expansions

Recordati Industria Chimica e Farmaceutica SPA (IT:REC) has released an update.

Recordati Industria Chimica e Farmaceutica SPA reported strong financial growth in the first nine months of 2024, with revenues rising by 12% to €1,743.1 million and EBITDA increasing by 11.8% to €665.7 million. The company’s performance was bolstered by robust gains in both the Specialty & Primary Care and Rare Diseases sectors, while strategic agreements like the acquisition of Enjaymo® from Sanofi further bolster its market position. Recordati also announced a new stock buyback program, highlighting its commitment to enhancing shareholder value.

For further insights into IT:REC stock, check out TipRanks’ Stock Analysis page.